Company Overview and News


Add IMC
to your dashboard

Headline News

Immuron set to commence Clostridium Difficile Infection study in Israel

2017-08-09 proactiveinvestors.com.au
Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

Immuron targets cash injection

2017-06-08 proactiveinvestors.com.au
Immuron (ASX:IMC) has been granted a trading halt by the ASX, pending details of a capital raising.

Immuron looks to NASDAQ

2017-05-30 proactiveinvestors.com.au
Immuron (ASX:IMC) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Immuron gets ready to begin clinical trial of new drug candidate

2017-05-10 proactiveinvestors.com.au
Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI).

Immuron enrols first patient in paediatric fatty liver trial in the U.S.

2017-02-06 proactiveinvestors.com.au
Immuron (ASX:IMC) has enrolled the first patient for its paediatric NAFLD (non-alcoholic fatty liver disease) Phase II trial conducted by Emory University in Georgia, U.S.

Immuron Ltd to develop vaccine for deadly bacillary dysentery with U.S. Army research unit

2016-06-21 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Immuron Ltd in ASX trading halt

2016-05-26 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Immuron Ltd has no safety issues in Phase II fatty liver trial

2016-05-25 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Appendix 3B & 708A Notice

2016-04-18 asx.com.au

Immuron Ltd tap into U.S. market for travellers’ tablets with CVS Pharmacy

2016-04-14 proactiveinvestors.com.au
Immuron Ltd (ASX:IMC) is focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.

Appendix 3B - Issue of Securities

2016-02-24 asx.com.au

SeeThruEquity Initiates Coverage on Immuron Ltd. (ASX: IMC.AX, OTCQB: IMROY) with a Price Target of A$1.37

2016-02-02 accesswire
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Immuron Ltd. (ASX: IMC.AX, OTCQB: IMROY) with a Price Target of A$1.37.